<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897908/" ref="ordinalpos=2092&amp;ncbi_uid=3186667&amp;link_uid=PMC2897908" image-link="/pmc/articles/PMC2897908/figure/F2/" class="imagepopup">Figure 2. Inhibitors of the MAPK <span class="highlight" style="background-color:">pathway</span>.  From: Targeting the MAPK <span class="highlight" style="background-color:">Pathway</span> in Melanoma: Why some approaches succeed and other fail. </a></div><br /><div class="p4l_captionBody">Schematic representation of key targets and pharmacological agents that inhibit MAPK signaling proteins. Imitanib, dastinib and sorafenib inhibit receptor tyrosine kinases thereby preventing activation of mitogen dependent activation in the MAPK pathway. Tipifarnib, R115777, BMS-214662 and L-778123 are selective to RAS while PLX4032, RAF-265 and XL281 specifically target activated B-RAF and are at various stages of clinical development. AZD6244, U0126, PD0325901, CI-1040, XL518, AZD8330, ARRY-162 and ARRY-300 inhibit MEK 1/2 while curcumin, plumbagin and DHMEQ target IKKβand NFκB.</div></div>